Trans -acting Aptazyme for Conditional Gene Knockdown in Eukaryotic Cells
Shan Zhou,Meiyi Chen,Yi Yuan,Yan Xu,Qinlin Pu,Xilei Ai,Shuai Liu,Feng Du,Xin Huang,Juan Dong,Xin Cui,Zhuo Tang
DOI: https://doi.org/10.1016/j.omtn.2023.07.014
2023-07-18
Abstract:Trans-acting hammerhead ribozyme inherits the advantages of being the smallest and best-characterized RNA-cleaving ribozyme, offering high modularity and the ability to cleave any desired sequence without the aid of any protein, as long as the target sequence contains a cleavage site. However, achieving precise control over the trans -acting hammerhead ribozyme would enable safer and more accurate regulation of gene expression. Herein, we described an intracellular selection of hammerhead aptazyme that contains a theophylline aptamer on stem II based on toxin protein IbsC. Based on the intracellular selection, we obtained three new cis- acting hammerhead aptazymes. Moreover, the corresponding trans- acting aptazymes could be efficiently induced by theophylline to knock down different targeted genes in eukaryotic cells. Notably, the best one, T195 exhibited a ligand-dependent and dose-dependent response to theophylline, and the cleavage efficiency could be enhanced by incorporating multiplex aptazymes.
medicine, research & experimental